Granted Patent
B2
US 12,274,698 · App. 18/209,699 · Granted Apr 15, 2025
Bromocriptine formulations
Assignee:
VeroScience LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.
Claims (16)
1. The method of treating a metabolic disorder selected from the group consisting of type 2 diabetes, obesity, prediabetes, and hyperlipidemia in a subject which comprises administering to the subject an effective amount for treating the metabolic disorder of a pharmaceutical formulation comprising bromocriptine citrate and a triglyceride wherein the pharmaceutical formulation is soluble in water to at least 200 mg/L at 20° C.
2. The method of claim 1 wherein the pharmaceutical formulation further comprises an excipient.
3. The method of claim 2 wherein the excipient comprises citric acid.
4. The method of claim 2 wherein the triglyceride comprises castor oil.
5. The method of claim 3 wherein the excipient comprises a non-lactose short chain saccharide.
6. The method of claim 1 wherein the group further consists of cardiovascular disease.
7. The method of claim 1 wherein the group further consists of hypertension.
8. The method of claim 1 wherein the group further consists of congestive heart failure.
9. The method of claim 1 wherein the group further consists of renal disease.
10. The method of claim 1 wherein the pharmaceutical formulation provides a dose of at least about 0.1 mg of bromocriptine citrate.
11. The method of claim 1 wherein the pharmaceutical formulation is substantially free of free of magnesium and lactose.
12. The method of claim 1 wherein the pharmaceutical formulation provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 ml of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine citrate has been released at about 30 minutes.
13. The method of claim 1 wherein the pharmaceutical formulation contains no more than 3% total related substances as determined by HPLC analysis using detection of UV absorption at 300 nm following storage of the pharmaceutical formulation at a temperature of 40±2° C. at about 70±5% relative humidity for about 6 weeks.
14. The method of claim 1 which comprises administering the pharmaceutical formulation at a time of day that will increase central nervous system dopamine activity at the time of day of its natural circadian peak in healthy individuals of the same species and sex; and optionally wherein the pharmaceutical formulation is administered so as to increase dopaminergic activity within 4 hours of waking.
15. The method of claim 14 wherein the time of day is between 0400 and 1200 hours.
16. The method of claim 1 wherein the pharmaceutical formulation comprises a sub-lingual tablet.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 21, 2024
From: CINCOTTA, ANTHONY H.
To: VEROSCIENCE LLC
Reel/Frame 069432/0079 →
Continuity (4)
Division
16623183
Provisional Application
62573839
· Oct 18, 2017
References Cited (233)
US 941005A
· Brandt
· 1909
[cited by applicant]
US 3752814A
· Fluckiger
· 1973
[cited by applicant]
US 4654345A
· Cavanak
· 1987
[cited by applicant]
US 4659715A
· Meier et al.
· 1987
[cited by applicant]
US 4749709A
· Meier et al.
· 1988
[cited by applicant]
US 4783469A
· Meier et al.
· 1988
[cited by applicant]
US 4962197A
· Foley et al.
· 1990
[cited by applicant]
US 5006526A
· Meier et al.
· 1991
[cited by applicant]
US 5066495A
· Moro et al.
· 1991
[cited by applicant]
US 5186420A
· Beauchamp et al.
· 1993
[cited by applicant]
US 5344832A
· Cincotta et al.
· 1994
[cited by applicant]
US 5468755A
· Cincotta et al.
· 1995
[cited by applicant]
US 5496803A
· Meier et al.
· 1996
[cited by applicant]
US 5523082A
· Corbiere
· 1996
[cited by applicant]
US 5554623A
· Cincotta et al.
· 1996
[cited by applicant]
US 5565454A
· Cincotta
· 1996
[cited by applicant]
US 5585347A
· Meier et al.
· 1996
[cited by applicant]
US 5626860A
· Cincotta et al.
· 1997
[cited by applicant]
US 5635512A
· Cincotta et al.
· 1997
[cited by applicant]
US 5654313A
· Cincotta et al.
· 1997
[cited by applicant]
US 5668155A
· Cincotta et al.
· 1997
[cited by applicant]
US 5679685A
· Cincotta et al.
· 1997
[cited by applicant]
US 5688794A
· Meier et al.
· 1997
[cited by applicant]
US 5696128A
· Meier et al.
· 1997
[cited by applicant]
US 5700795A
· Meier et al.
· 1997
[cited by applicant]
US 5700800A
· Cincotta et al.
· 1997
[cited by applicant]
US 5712265A
· Meier et al.
· 1998
[cited by applicant]
US 5714519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716932A
· Meier et al.
· 1998
[cited by applicant]
US 5716933A
· Meier et al.
· 1998
[cited by applicant]
US 5716957A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716962A
· Cincotta et al.
· 1998
[cited by applicant]
US 5719160A
· Cincotta et al.
· 1998
[cited by applicant]
US 5731287A
· Meier et al.
· 1998
[cited by applicant]
US 5731312A
· Cincotta et al.
· 1998
[cited by applicant]
US 5741503A
· Cincotta et al.
· 1998
[cited by applicant]
US 5744477A
· Meier et al.
· 1998
[cited by applicant]
US 5750519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5756513A
· Meier et al.
· 1998
[cited by applicant]
US 5760047A
· Meier et al.
· 1998
[cited by applicant]
US 5792748A
· Meier et al.
· 1998
[cited by applicant]
US 5814638A
· Lee et al.
· 1998
[cited by applicant]
US 5830895A
· Cincotta et al.
· 1998
[cited by applicant]
US 5854255A
· Cincotta et al.
· 1998
[cited by applicant]
US 5866584A
· Cincotta et al.
· 1999
[cited by applicant]
US 5872127A
· Meier et al.
· 1999
[cited by applicant]
US 5872133A
· Meier et al.
· 1999
[cited by applicant]
US 5877183A
· Cincotta
· 1999
[cited by applicant]
US 5902811A
· Cincotta
· 1999
[cited by applicant]
US 5905083A
· Meier et al.
· 1999
[cited by applicant]
US 5952329A
· Cincotta et al.
· 1999
[cited by applicant]
US 6004972A
· Meier et al.
· 1999
[cited by applicant]
US 6071914A
· Meier et al.
· 2000
[cited by applicant]
US 6075020A
· Meier et al.
· 2000
[cited by applicant]
US 6855707B2
· Cincotta
· 2005
[cited by applicant]
US 7888310B2
· Cincotta
· 2011
[cited by applicant]
US 8021681B2
· Cincotta
· 2011
[cited by applicant]
US 8137992B2
· Cincotta
· 2012
[cited by applicant]
US 8137993B2
· Cincotta
· 2012
[cited by applicant]
US 8137994B2
· Cincotta
· 2012
[cited by applicant]
US 8431155B1
· Cincotta et al.
· 2013
[cited by applicant]
US 8613947B2
· Cincota et al.
· 2013
[cited by applicant]
US 8741918B2
· Cincotta
· 2014
[cited by applicant]
US 8821915B2
· Cincotta
· 2014
[cited by applicant]
US 8877708B2
· Cincotta
· 2014
[cited by applicant]
US 9192576B2
· Cincotta et al.
· 2015
[cited by applicant]
US 9205084B2
· Cincotta
· 2015
[cited by applicant]
US 9352025B2
· Cincotta
· 2016
[cited by applicant]
US 9364515B2
· Cincotta
· 2016
[cited by applicant]
US 9415005B2
· Cincotta
· 2016
[cited by applicant]
US 9522117B2
· Cincotta et al.
· 2016
[cited by applicant]
US 9655865B2
· Cincotta
· 2017
[cited by applicant]
US 9700555B2
· Cincotta et al.
· 2017
[cited by applicant]
US 9895422B2
· Cincotta
· 2018
[cited by applicant]
US 9925186B2
· Cincotta
· 2018
[cited by applicant]
US 9993474B2
· Cincotta et al.
· 2018
[cited by applicant]
US 9999653B2
· Cincotta
· 2018
[cited by applicant]
US 20010016582A1
· Cincotta
· 2001
[cited by applicant]
US 20010049350A1
· Cincotta et al.
· 2001
[cited by applicant]
US 20020146400A1
· Cincotta
· 2002
[cited by applicant]
US 20040028613A1
· Quay
· 2004
[cited by applicant]
US 20040077679A1
· Cincotta
· 2004
[cited by applicant]
US 20040081678A1
· Cincotta
· 2004
[cited by applicant]
US 20040102383A1
· Cincotta et al.
· 2004
[cited by applicant]
US 20040220190A1
· Cincotta
· 2004
[cited by applicant]
US 20050054652A1
· Cincotta
· 2005
[cited by applicant]
US 20050054734A1
· Cincotta
· 2005
[cited by applicant]
US 20050215558A1
· Cincotta
· 2005
[cited by applicant]
US 20060258589A1
· McTavish
· 2006
[cited by applicant]
US 20080200453A1
· Cincotta
· 2008
[cited by applicant]
US 20090137598A1
· Cincotta
· 2009
[cited by applicant]
US 20100035886A1
· Nivorozhkin et al.
· 2010
[cited by applicant]
US 20130274246A1
· Cincotta
· 2013
[cited by applicant]
US 20140051685A1
· Cincotta
· 2014
[cited by applicant]
US 20150011554A1
· Cincotta et al.
· 2015
[cited by applicant]
US 20170209539A1
· Cincotta
· 2017
[cited by applicant]
US 20170305898A1
· Cincotta
· 2017
[cited by applicant]
US 20170340271A1
· Cincotta
· 2017
[cited by applicant]
US 20180177874A1
· Cincotta
· 2018
[cited by applicant]
US 20190160059A1
· Cincotta et al.
· 2019
[cited by applicant]
US 20210401824A1
· Cincotta
· 2021
[cited by applicant]
US 20220125379A1
· Cincotta
· 2022
[cited by applicant]
US 20220142960A1
· Cincotta et al.
· 2022
[cited by applicant]
CA 2166204
· 2009
[cited by applicant]
CN 102283844
· 2014
[cited by applicant]
CN 102727894
· 2015
[cited by applicant]
GB 2192541
· 1988
[cited by applicant]
JP H02121919
· 1990
[cited by applicant]
JP 2021500357
· 2021
[cited by applicant]
WO WO2002083141
· 2002
[cited by applicant]
WO WO2009091576
· 2009
[cited by applicant]
WO WO2013165902
· 2013
[cited by applicant]
WO WO2017184875
· 2017
[cited by applicant]
Office Action in Japanese Appln. No. 2023-018110, mailed on Apr. 2, 2024, 5 pages (with English translation).
[cited by applicant]
Granchi et al., “Anti-cancer agents counteracting tumor glycolysis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Sun et al., “Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
[No Author Listed], “Dissolution,” General Chapter 711, U.S. Pharmacopoeia (USP), 34th ed., Dec. 1, 2011, 8 pages.
[cited by applicant]
Alkarakooly et al., “Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells,” PLOS One, Oct. 23, 2018, 13(10): e0206182.
[cited by applicant]
Ashton et al., “Oxidative Phosphorylation as an Emerging Target in Cancer Therapy,” Clinical Cancer Research, 2018, 24(11):2482-2490.
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, 66(1):1-19.
[cited by applicant]
Cincotta et al., “Novel benzophenothiazinium photosensitizers: preliminary in-vivo results,” Photodynamic Therapy: Mechanisms II, SPIE, 1990, 1203:202-210.
[cited by applicant]
Cincotta et al., “Novel Phenothiazinium Photosensitizers for Photodynamic Therapy,” SPIE Proceedings, Advances in Photochemotherapy, 1988, 997:145-153.
[cited by applicant]
Cincotta et al., “Novel Photodynamic Effects of a Benzophenothiazine on Two Different Murine Sarcomas,” Cancer Research, Mar. 1, 1994, 54:1249-1258.
[cited by applicant]
Cincotta et al., “Novel red absorbing benozoaphenoxazinium and benzoaphenothiazinium photosensitizers: in vitro evaluation,” PhotoChemistry and PhotoBiology, Nov. 1987, 46(5):751-758.
[cited by applicant]
Cincotta et al., “Phototoxicity, Redox Behavior, and Pharmacokinetics of Benzophenoxazine Analogues in EMT-6 Murine Sarcoma Cells,” Cancer Research, Jun. 1, 1993, 53:2571-2580.
[cited by applicant]
Deni et al., “Glucose-functionalized amino-OPEs as biocompatible photosensitizers in PDT,” European Journal of Medicinal Chemistry, Jan. 28, 2016, 11:58-71.
[cited by applicant]
Detty et al., “Current clinical and preclinical photosensitizers for use in photodynamic therapy,” Journal of Medicinal Chemistry, 2004, 47(16):3897-3915.
[cited by applicant]
Dietrich et al., “Non-alcoholic fatty liver disease, obesity and the metabolic syndrome,” Best Practice & Research Clinical Gastroenterology, 2014, 28:637-653.
[cited by applicant]
EP Extended European Search Report in European Appln No. 18868516.8, dated Jun. 29, 2021, 8 pages.
[cited by applicant]
Fadlan et al., “Synthesis, photophysical properties, and photodynamic activity of positional isomers of TFPP-glucose conjugates,” Bioorganic & Medicinal Chemistry, Feb. 19, 2018, 26(8):1848-1858.
[cited by applicant]
Fadok et al., “Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: roles of proteases,” Journal of Immunology, 2001, 166:6847-6854.
[cited by applicant]
Fan et al., “Hyperglycemia enhances the effectiveness of PDT,” Proceedings of SPIE, 1995, 2392:36-39.
[cited by applicant]
Feng et al., “Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death,” Photochemical & Photobiological Science, Oct. 9, 2014, 13:1792-1803.
[cited by applicant]
Foley et al., “Structure and Properties of Novel BenzoαPhenoxazinium Photochemotherapeutic Agents,” SPIE Proceedings, New Directions in Photodynamic Therapy, 1987, 847:90-95.
[cited by applicant]
Foultier et al., “Photosensitization of L12 10 leukemic cells by argon laser irradiation after incubation with haematoporphyrin derivative and rhodamine 123,” J Photochem. Photobiol. B: Biol. 1991, 10:119-132.
[cited by applicant]
Frimberger et al., “Photodynamic Therapy of Naturally Occurring Tumors in Animals Using a Novel Benzophenothiazine Photosensitizer,” Clinical Cancer Research, 1998, 4:2207-2218.
[cited by applicant]
Gould, “Salt selection for basic drugs,” International Journal of Pharmaceutics, 1986, 33:201-217.
[cited by applicant]
Granchi et al., “Anti-cancer agents counteracting tumor glycolsis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Hayashi et al., “A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages,” Molecular Cancer Therapeutics, 2015, 14(2):452-460.
[cited by applicant]
Hendrzak-Henion et al., “Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy,” Photochemistry and Photobiology, 1999, 69(5):575-581.
[cited by applicant]
Lin et al., “Lysosomal Localization and Mechanism of Uptake of Nile Blue Photosensitizers in Tumor Cells,” Cancer Research, 1991, 51:2710-2719.
[cited by applicant]
Lin et al., “Photosensitization, Uptake, and Retention of Phenoxazine Nile Blue Derivatives in Human Bladder Carcinoma Cells,” Cancer Research, 1991, 51:1109-1116.
[cited by applicant]
Liu et al., “EtNBSe-PDT inhibited proliferation and induced autophagy of HNE-1 cells via downregulating the Wnt/beta-catenin signaling pathway,” Photodiagnosis and Photodynamic Therapy, Mar. 1, 2019, 26:65-72.
[cited by applicant]
Martin et al., “A concomitant ATP-depleting strategy markedly enhances anticancer agent activity,” Apoptosis, 2001, 6(1/2):125-131.
[cited by applicant]
Nelson et al., “Glucose administration combined with photodynamic therapy of cancer improves therapeutic efficacy,” Lasers in Surgery and Medicine, 1992, 12:153-158.
[cited by applicant]
Nishie et al., “Excellent antitumor effects for gastrointestinal cancers using photodynamic therapy with a novel glucose conjugated chlorin e6,” Biochemical and Biophysical Research Communications, Jan. 2018, 496(4):120…
[cited by applicant]
Oberdanner et al., “Glucose is Required to Maintain High ATP-levels for the Energy-utilizing Steps During PDT-induced Apoptosis,” Photochemistry and Photobiology, 2002, 76(6):695-703.
[cited by applicant]
Osinsky et al., “Tumour pH under induced hyperglycemia and efficacy of chemotherapy,” Anticancer Research, 1987, 7(2):199-201.
[cited by applicant]
Pan, “Industrial Pharmaceutics,” China Medical Science and Technology Press, the first printing of the 3rd edition, Aug. 2015, p. 47 (Partial English Translation only).
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/056554, dated Apr. 21, 2020, 15 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2017/028656, mailed on Oct. 23, 2018, 6 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020/052278, dated Mar. 15, 2022, 7 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2017/028656, mailed on Jul. 7, 2017, 13 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/052278, dated Feb. 10, 2021, 9 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/056554, dated, Jan. 3, 2019, 17 pages.
[cited by applicant]
Pelicano et al., “Glycolysis inhibition for anticancer treatment,” Oncogene, 2006, 25:4633-4646.
[cited by applicant]
Pukngam et al., “Development and Validation of a Stability-Indicating HPLC Method for Determination of Bromocriptine Mesylate in Bulk Drug and Tablets,” Current Pharmaceutical Analysis, 2013, 9:92-101.
[cited by applicant]
Ramu et al., “Glucose-appended platinum (II)-BODIPY conjugates for targeted photodynamic therapy in red light,” Inorganic Chemistry, Feb. 5, 2018, 57(4):1717-1726.
[cited by applicant]
Rathbone et al., academia.edu [Online], “Modified-Release Drug Delivery Technology,” Marcel Dekker, Inc., 2003, [Retrieved on Nov. 23, 2018], retrieved from: URL<https:www.academia.edu/28583222/Modified-Release_Drug_Del…
[cited by applicant]
Reiter et al., “Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities,” Journal of Immunology, 1999, 163:1730-1732.
[cited by applicant]
Rowe et al., “Mannitol,” Handbook of Pharmaceutical Excipients, 7th ed., 2012, pp. 479-482.
[cited by applicant]
Rowe et al., “Stearic Acid,” Handbook of Pharmaceutical Excipients, 6th ed, 2009, pp. 697-699.
[cited by applicant]
Sauter et al., “Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells,” Journal of Experimental Medici…
[cited by applicant]
Singh et al., “Dosage Forms: Non-Parenteral,” Encyclopedia of Pharmaceutical Technology, 2008, 749-761.
[cited by applicant]
Stahl et al., “Pharmaceutical Salts: Properties, Selection, and Use,” Wiley-VCH, IUPAC, 2002, 329-345.
[cited by applicant]
Sun et al., “Neutrphils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
Uruma et al., “Synthesis and biological evaluation of glucose conjugated phthalocyanine as a second-generation photosensitizer,” Bioorganic & Medicinal Chemistry, Jun. 4, 2019, 27:3279-3284.
[cited by applicant]
Vicchi et al., “Dopaminergic drugs in type 2 diabetes and glucose homeostasis,” Pharmacological Research, 2016, 109:74-80.
[cited by applicant]
Office Action in European Appln No. 21189773.1, mailed on Sep. 16, 2024, 5 pages.
[cited by applicant]